pdufa.bio

COSENTYX (secukinumab)

Updated ยทnext FDA decision on the calendar

COSENTYX (secukinumab) The FDA approved it on Mar 13, 2026. 1 FDA decision on record below. Every date links its source.

NVS catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

We track 1 catalyst event for this program: 0 upcoming and 1 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

PDUFA · Mar 13, 2026 ✓ ApprovedNVS

Questions

When is COSENTYX (secukinumab)'s next FDA decision or readout?

No upcoming catalyst is on our calendar for COSENTYX (secukinumab); 1 FDA decision is on record below.

What happened at COSENTYX (secukinumab)'s most recent FDA decision?

On Mar 13, 2026 the FDA approved the application. The decision page carries the source document and the measured share-price reaction.

Has COSENTYX (secukinumab) been approved by the FDA?

Yes. The FDA approved an application for COSENTYX (secukinumab) on Mar 13, 2026; the decision page linked above carries the source.

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.